U.S. Defense Secretary Pete Hegseth announced a new screening program to test the testosterone levels of service members for potential deficiencies.
The initiative marks a shift in military health priorities by focusing on hormone levels to optimize troop performance. It raises questions among medical professionals regarding the ethics and efficacy of mass screening for testosterone.
Under the new plan, annual testosterone screening will be required for service members aged 30 and older [1]. Service members under 30 may volunteer for the testing [2]. Hegseth said the program is intended to ensure that troops can operate at their "absolute best" [3].
While the screening for older troops is mandatory, any subsequent medical intervention remains optional. Hegseth said that receiving testosterone replacement therapy would be voluntary [4].
The program has drawn scrutiny from the medical community. One medical expert said that testing all service members for testosterone could backfire and raise medical-ethical concerns [5]. These concerns center on the potential for over-diagnosis, and the risks associated with long-term hormone therapy.
There remains some ambiguity regarding the scope of the program. Some reports indicate the testing applies broadly to troops 30 and over [1], while other sources noted it was unclear if the plan would affect women [6].
The Pentagon's move comes as part of a broader effort to maximize the physical and mental readiness of the U.S. military. By identifying deficiencies early, the Department of Defense aims to maintain a high standard of operational capability across the force.
“"We need to ensure our troops are operating at their absolute best."”
This program represents an attempt to apply biological optimization to military readiness. By institutionalizing hormone screening, the Pentagon is treating testosterone levels as a key metric of combat effectiveness. However, the pushback from medical experts suggests a tension between the military's desire for peak performance and the clinical standards for diagnosing hormone deficiencies, which typically require symptomatic evidence rather than just a numerical value from a mass screen.
